Phase 2 AMG 714 in Rheumatoid Arthritis

Amgen180 enrolled

Overview

Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

180

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Diagnosis of RA - Exclusion Criteria: No prior biologic treatment for RA \-

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.